In the Research Letter, “Shift From Adalimumab Originator to Biosimilars in Denmark,” Jensen et al¹ describe the marked savings Denmark experienced after a nationwide switch from the proprietary version of adalimumab (Humira) to the biosimilar. The extent of these savings and the rapidity of the switch, even absent a substitution mandate, mirrors similar successes with other biologic biosimilar campaigns in Denmark (and some European countries). In contrast, in the US, although the Food and Drug Administration has approved biosimilars for adalimumab, they will not enter the market until 2023 owing to patent disputes with AbbVie, the manufacturer of Humira. Jensen et al¹ highlight the schemes other manufacturers have taken to dissuade biosimilars from formulary inclusion in the US, including use of rebate traps. In 2013, Humira had an annual postrebate price of $19 000, which had increased to $38 000 by 2018, meaning the delay in market entry of a biosimilar has a big effect not only on increasing spending for Humira, but also increasing spending on the biosimilar, which will be priced using Humira’s price as an anchor.

在研究信“从阿达木单抗的研发者向丹麦的生物仿制药的转变”中，詹森等人[ ^1]描述了丹麦从全国范围内从阿达木单抗（Humira）的专有版本转向生物仿制药后获得的显着节省。这些节省的程度和转换的速度，甚至没有替代要求，也反映了丹麦（和某些欧洲国家）其他生物仿制药活动的类似成功。相比之下，在美国，尽管美国食品药品管理局已经批准了阿达木单抗的生物仿制药，但由于与Humira制造商AbbVie的专利纠纷，它们直到2023年才进入市场。詹森（Jensen）等人¹强调其他制造商已采取的措施，以劝阻生物仿制药免于在美国纳入处方，包括使用回扣诱集装置。2013年，Humira的年度回扣价格为19 000美元，到2018年已增加到38 000美元，这意味着生物仿制药进入市场的延迟不仅对Humira的支出增加有很大影响，而且还增加了对生物仿制药的支出，它将以Humira的价格作为锚点进行定价。